Posters

Recurrent pterygium treatment with plasma rich in growth factors (PRGF) and PRGF fibrine membrane (mPRGF) and eye drops: two-case report

Poster Details

First Author: I.Mogollón Giralt SPAIN

Co Author(s):    J. Dabad Moreno   A. Boto de los Bueis   A. Del Hierro Zarzuelo   P. Vázquez Colomo   A. De la Hoz Polo   I. Villalaín Rodes     

Abstract Details

Purpose:

Pterygium recurrence is a dreaded complication after pterygium removal. Different techniques have been used to treat it, being conjunctival autograft the most extended. Hereby we present 2 cases of recurrent pterygium after excision and conjunctival autograft years before treated with plasma rich in growth factors (PRGF) eye drops and PRGF fibrin membrane (mPRGF) with a succesfull follow-up. Consisting on the preparation of autologous formulations obtained from the patient's blood, both have the capability to induce wound regeneration, bactericidal and bacteriostatic activity, anti-inflammatory and antifibrotic potential. Moreover, these characteristics have been evidenced in clinical studies in the ophthalmology field.

Setting:

Department of Ophthalmology. Hospital Universitario La Paz. Madrid, Spain.

Methods:

Under retrobulbar anesthesia, affected eyes underwent surgical removal of the whole pterygium and subconjunctival fibrovascular tissue, then measured mPRGF was placed and sutured with Nylon 10-0 to the conjunctiva, finally triamcinolone acetonide was injected subconjunctivally. To obtain mPRGF and eye drops, patient blood samples were centrifuged in an Endoret System centrifuge (Biotechnology Institute, Spain) and separated into different products following the manufacturer instructions. After the surgery, the patients underwent a topical treatment with dexamethasone and tobramycin eye drops. One week after the surgery, the PRGF eye drops were applied 4 times per day for 6 weeks in the affected eye.

Results:

In both cases, treated eyes with mPRGF didn´t present any relapse during the 24 months follow-up after surgery. The best corrected visual acuity improved in both patients treated with mPRGF. No ophthalmological complications were observed neither with the use of mPRGF nor with the associated treatments. Patients showed no pain, no discomfort, or any other symptoms during the postoperative follow-up period. To the best of our knowledge, this is the first report of mPRGF being used as a surgical technique for recurrent pterygium with encouraging results and this may become an option in the treatment of recurrent pterygium.

Conclusions:

The use of mPRGF and PRGF eye drops is an effective and safe method of surgical treatment for recurrent pterygium that provides good tissue regeneration and prevents relapses due to its anti-inflammatory and antifibrotic properties. It can be considered a novel technique for the treatment of recurrent pterygium with an adequate follow-up time and good functional and structural results. Due to the low number of patients, further studies will be needed to properly confirm these results.

Financial Disclosure:

None

Financial Disclosure:

None